GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2010

Roche Expands Agreement with b3 bio to Include Therapeutic Technologies

  • b3 bio signed an agreement with Roche to source and develop innovative early-stage technologies that could result in potential therapeutic benefits. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as provide development funds.

    b3 bio and Roche started their partnership in July, 2008. The initial arrangement focused on the development of delivery systems for a range of drug candidates and diagnostic cargos.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?